Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IOM Flags Top 100 Comparative Effectiveness Research Priorities; Drugs Mentioned Rarely

This article was originally published in The Pink Sheet Daily

Executive Summary

Among the top 25 priority CER topics, only five specifically mention including pharma or biotech products in the studies.

You may also be interested in...



PCORI To Solicit More Head-To-Head Comparative Studies

The Patient-Centered Outcomes Research Institute announces plans to encourage the submission of more proposals for head-to-head clinical comparative effectiveness studies. Among the research topics the institute will encourage are the Institute of Medicine’s top 100 priorities and recommendations from America’s Health Insurance Plans.

CDC Issues $10 Million In Comparative Effectiveness Research Awards

When it comes to comparative effectiveness research, the Centers for Disease Control and Prevention typically are not at the forefront of government agencies conducting activities in this space

CDC Issues $10 Million In Comparative Effectiveness Research Awards

When it comes to comparative effectiveness research, the Centers for Disease Control and Prevention typically are not at the forefront of government agencies conducting activities in this space

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel